The global market for Decentralized & Digitalized Clinical Trials was valued at US$ 8216 million in the year 2023 and is projected to reach a revised size of US$ 17440 million by 2030, growing at a CAGR of 11.4% during the forecast period.
Decentralized & Digitalized Clinical Trials are an innovative approach to conducting clinical research. They aim to move away from the traditional model that requires participants to visit a central research site (such as a hospital or a dedicated research facility) for most of the trial - related activities. Instead, DCTs bring various aspects of the trial to the participants' local environment, such as their homes or local healthcare centers.
North American market for Decentralized & Digitalized Clinical Trials is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Decentralized & Digitalized Clinical Trials is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Decentralized & Digitalized Clinical Trials in Oncology is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Decentralized & Digitalized Clinical Trials include Medidata, IQVIA, Labcorp, PRA Health Sciences, Parexel, ICON, Oracle, Medpace, Patheon, Signant Health, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Decentralized & Digitalized Clinical Trials, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Decentralized & Digitalized Clinical Trials.
The Decentralized & Digitalized Clinical Trials market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Decentralized & Digitalized Clinical Trials market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Decentralized & Digitalized Clinical Trials companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Medidata
IQVIA
Labcorp
PRA Health Sciences
Parexel
ICON
Oracle
Medpace
Patheon
Signant Health
Syneos Health
CRF Health
Clinical Ink
Medable
Obvio Health
Fortrea
ProPharma
Cloudbyz
Science 37
Advarra
Medrio
Tigermed
Zhejiang Taimei Medical Technology
Shanghai Yaocheng Health Technology
Segment by Type
Web-based
Cloud-based
Segment by Application
Oncology
Cardiovascular
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Decentralized & Digitalized Clinical Trials company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Decentralized & Digitalized Clinical Trials 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Web-based
1.2.3 Cloud-based
1.3 麻豆原创 by Application
1.3.1 Global Decentralized & Digitalized Clinical Trials 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Oncology
1.3.3 Cardiovascular
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Decentralized & Digitalized Clinical Trials 麻豆原创 Perspective (2019-2030)
2.2 Global Decentralized & Digitalized Clinical Trials Growth Trends by Region
2.2.1 Global Decentralized & Digitalized Clinical Trials 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Decentralized & Digitalized Clinical Trials Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Decentralized & Digitalized Clinical Trials Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Decentralized & Digitalized Clinical Trials 麻豆原创 Dynamics
2.3.1 Decentralized & Digitalized Clinical Trials Industry Trends
2.3.2 Decentralized & Digitalized Clinical Trials 麻豆原创 Drivers
2.3.3 Decentralized & Digitalized Clinical Trials 麻豆原创 Challenges
2.3.4 Decentralized & Digitalized Clinical Trials 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Decentralized & Digitalized Clinical Trials Players by Revenue
3.1.1 Global Top Decentralized & Digitalized Clinical Trials Players by Revenue (2019-2024)
3.1.2 Global Decentralized & Digitalized Clinical Trials Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Decentralized & Digitalized Clinical Trials 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Decentralized & Digitalized Clinical Trials Revenue
3.4 Global Decentralized & Digitalized Clinical Trials 麻豆原创 Concentration Ratio
3.4.1 Global Decentralized & Digitalized Clinical Trials 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Decentralized & Digitalized Clinical Trials Revenue in 2023
3.5 Global Key Players of Decentralized & Digitalized Clinical Trials Head office and Area Served
3.6 Global Key Players of Decentralized & Digitalized Clinical Trials, Product and Application
3.7 Global Key Players of Decentralized & Digitalized Clinical Trials, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Decentralized & Digitalized Clinical Trials Breakdown Data by Type
4.1 Global Decentralized & Digitalized Clinical Trials Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Decentralized & Digitalized Clinical Trials Forecasted 麻豆原创 Size by Type (2025-2030)
5 Decentralized & Digitalized Clinical Trials Breakdown Data by Application
5.1 Global Decentralized & Digitalized Clinical Trials Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Decentralized & Digitalized Clinical Trials Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Decentralized & Digitalized Clinical Trials 麻豆原创 Size (2019-2030)
6.2 North America Decentralized & Digitalized Clinical Trials 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Decentralized & Digitalized Clinical Trials 麻豆原创 Size by Country (2019-2024)
6.4 North America Decentralized & Digitalized Clinical Trials 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Decentralized & Digitalized Clinical Trials 麻豆原创 Size (2019-2030)
7.2 Europe Decentralized & Digitalized Clinical Trials 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Decentralized & Digitalized Clinical Trials 麻豆原创 Size by Country (2019-2024)
7.4 Europe Decentralized & Digitalized Clinical Trials 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Decentralized & Digitalized Clinical Trials 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Decentralized & Digitalized Clinical Trials 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Decentralized & Digitalized Clinical Trials 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Decentralized & Digitalized Clinical Trials 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Decentralized & Digitalized Clinical Trials 麻豆原创 Size (2019-2030)
9.2 Latin America Decentralized & Digitalized Clinical Trials 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Decentralized & Digitalized Clinical Trials 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Decentralized & Digitalized Clinical Trials 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Decentralized & Digitalized Clinical Trials 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Decentralized & Digitalized Clinical Trials 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Decentralized & Digitalized Clinical Trials 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Decentralized & Digitalized Clinical Trials 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Medidata
11.1.1 Medidata Company Details
11.1.2 Medidata Business Overview
11.1.3 Medidata Decentralized & Digitalized Clinical Trials Introduction
11.1.4 Medidata Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.1.5 Medidata Recent Development
11.2 IQVIA
11.2.1 IQVIA Company Details
11.2.2 IQVIA Business Overview
11.2.3 IQVIA Decentralized & Digitalized Clinical Trials Introduction
11.2.4 IQVIA Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.2.5 IQVIA Recent Development
11.3 Labcorp
11.3.1 Labcorp Company Details
11.3.2 Labcorp Business Overview
11.3.3 Labcorp Decentralized & Digitalized Clinical Trials Introduction
11.3.4 Labcorp Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.3.5 Labcorp Recent Development
11.4 PRA Health Sciences
11.4.1 PRA Health Sciences Company Details
11.4.2 PRA Health Sciences Business Overview
11.4.3 PRA Health Sciences Decentralized & Digitalized Clinical Trials Introduction
11.4.4 PRA Health Sciences Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.4.5 PRA Health Sciences Recent Development
11.5 Parexel
11.5.1 Parexel Company Details
11.5.2 Parexel Business Overview
11.5.3 Parexel Decentralized & Digitalized Clinical Trials Introduction
11.5.4 Parexel Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.5.5 Parexel Recent Development
11.6 ICON
11.6.1 ICON Company Details
11.6.2 ICON Business Overview
11.6.3 ICON Decentralized & Digitalized Clinical Trials Introduction
11.6.4 ICON Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.6.5 ICON Recent Development
11.7 Oracle
11.7.1 Oracle Company Details
11.7.2 Oracle Business Overview
11.7.3 Oracle Decentralized & Digitalized Clinical Trials Introduction
11.7.4 Oracle Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.7.5 Oracle Recent Development
11.8 Medpace
11.8.1 Medpace Company Details
11.8.2 Medpace Business Overview
11.8.3 Medpace Decentralized & Digitalized Clinical Trials Introduction
11.8.4 Medpace Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.8.5 Medpace Recent Development
11.9 Patheon
11.9.1 Patheon Company Details
11.9.2 Patheon Business Overview
11.9.3 Patheon Decentralized & Digitalized Clinical Trials Introduction
11.9.4 Patheon Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.9.5 Patheon Recent Development
11.10 Signant Health
11.10.1 Signant Health Company Details
11.10.2 Signant Health Business Overview
11.10.3 Signant Health Decentralized & Digitalized Clinical Trials Introduction
11.10.4 Signant Health Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.10.5 Signant Health Recent Development
11.11 Syneos Health
11.11.1 Syneos Health Company Details
11.11.2 Syneos Health Business Overview
11.11.3 Syneos Health Decentralized & Digitalized Clinical Trials Introduction
11.11.4 Syneos Health Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.11.5 Syneos Health Recent Development
11.12 CRF Health
11.12.1 CRF Health Company Details
11.12.2 CRF Health Business Overview
11.12.3 CRF Health Decentralized & Digitalized Clinical Trials Introduction
11.12.4 CRF Health Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.12.5 CRF Health Recent Development
11.13 Clinical Ink
11.13.1 Clinical Ink Company Details
11.13.2 Clinical Ink Business Overview
11.13.3 Clinical Ink Decentralized & Digitalized Clinical Trials Introduction
11.13.4 Clinical Ink Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.13.5 Clinical Ink Recent Development
11.14 Medable
11.14.1 Medable Company Details
11.14.2 Medable Business Overview
11.14.3 Medable Decentralized & Digitalized Clinical Trials Introduction
11.14.4 Medable Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.14.5 Medable Recent Development
11.15 Obvio Health
11.15.1 Obvio Health Company Details
11.15.2 Obvio Health Business Overview
11.15.3 Obvio Health Decentralized & Digitalized Clinical Trials Introduction
11.15.4 Obvio Health Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.15.5 Obvio Health Recent Development
11.16 Fortrea
11.16.1 Fortrea Company Details
11.16.2 Fortrea Business Overview
11.16.3 Fortrea Decentralized & Digitalized Clinical Trials Introduction
11.16.4 Fortrea Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.16.5 Fortrea Recent Development
11.17 ProPharma
11.17.1 ProPharma Company Details
11.17.2 ProPharma Business Overview
11.17.3 ProPharma Decentralized & Digitalized Clinical Trials Introduction
11.17.4 ProPharma Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.17.5 ProPharma Recent Development
11.18 Cloudbyz
11.18.1 Cloudbyz Company Details
11.18.2 Cloudbyz Business Overview
11.18.3 Cloudbyz Decentralized & Digitalized Clinical Trials Introduction
11.18.4 Cloudbyz Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.18.5 Cloudbyz Recent Development
11.19 Science 37
11.19.1 Science 37 Company Details
11.19.2 Science 37 Business Overview
11.19.3 Science 37 Decentralized & Digitalized Clinical Trials Introduction
11.19.4 Science 37 Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.19.5 Science 37 Recent Development
11.20 Advarra
11.20.1 Advarra Company Details
11.20.2 Advarra Business Overview
11.20.3 Advarra Decentralized & Digitalized Clinical Trials Introduction
11.20.4 Advarra Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.20.5 Advarra Recent Development
11.21 Medrio
11.21.1 Medrio Company Details
11.21.2 Medrio Business Overview
11.21.3 Medrio Decentralized & Digitalized Clinical Trials Introduction
11.21.4 Medrio Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.21.5 Medrio Recent Development
11.22 Tigermed
11.22.1 Tigermed Company Details
11.22.2 Tigermed Business Overview
11.22.3 Tigermed Decentralized & Digitalized Clinical Trials Introduction
11.22.4 Tigermed Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.22.5 Tigermed Recent Development
11.23 Zhejiang Taimei Medical Technology
11.23.1 Zhejiang Taimei Medical Technology Company Details
11.23.2 Zhejiang Taimei Medical Technology Business Overview
11.23.3 Zhejiang Taimei Medical Technology Decentralized & Digitalized Clinical Trials Introduction
11.23.4 Zhejiang Taimei Medical Technology Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.23.5 Zhejiang Taimei Medical Technology Recent Development
11.24 Shanghai Yaocheng Health Technology
11.24.1 Shanghai Yaocheng Health Technology Company Details
11.24.2 Shanghai Yaocheng Health Technology Business Overview
11.24.3 Shanghai Yaocheng Health Technology Decentralized & Digitalized Clinical Trials Introduction
11.24.4 Shanghai Yaocheng Health Technology Revenue in Decentralized & Digitalized Clinical Trials Business (2019-2024)
11.24.5 Shanghai Yaocheng Health Technology Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
Medidata
IQVIA
Labcorp
PRA Health Sciences
Parexel
ICON
Oracle
Medpace
Patheon
Signant Health
Syneos Health
CRF Health
Clinical Ink
Medable
Obvio Health
Fortrea
ProPharma
Cloudbyz
Science 37
Advarra
Medrio
Tigermed
Zhejiang Taimei Medical Technology
Shanghai Yaocheng Health Technology
听
听
*If Applicable.
